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Abstract
The antimicrobial or antagonistic activity of probiotics is an important property that
includes  the  production  of  antimicrobial  compounds,  competitive  exclusion  of
pathogens, enhancement of the intestinal barrier function and others. There are many
methods to ascertain probiotic properties, including various in vitro and in vivo methods.
The in vivo methods include various modifications of the spot‐on lawn assay, agar well
diffusion assay (AWDA), co‐culturing methods, usage of cell lines and others. In many
cases in vitro antagonist activity is observed, but in real settings it is not observed. The
in vivo methods mainly used are animal models; however, their use is being restricted
according to the European legislation OJ L136. The justification of animal models is also
questionable as the results of studies on animals do not predict the same results for
humans. The use of replacement alternative methods, for example incorporating human
cells and tissues, avoids such confounding variables. Most important studies are double‐
blinded randomized clinical trials; however, these studies are difficult to perform as it
is not easy to achieve uniform conditions. There is a clear need for more elaborate assays
that would better represent the complex interactions between the probiotics and the
final host. This complex situation is a challenge for scientists.
Keywords: antimicrobial effect, in vitro methods, in vivo methods, pathogens, probiot‐
ics
1. Introduction
Throughout the history of microbiology, most human studies have been focused on the disease‐
causing organisms found on or in people; whilst fewer studies have examined the benefits of
the resident bacteria. However, we are surrounded by beneficial microorganisms that live in or
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on the human body. The intestinal microbiota is very well adapted, exceptionally stable and
very specific for each individual. In normal conditions of stable functioning of the digestive
system, neutral and beneficial microorganisms dominate. It is estimated that there are 100 trillion
microorganisms in the intestine of a human adult and this is 10 times larger than the number of
cells in the human body [1, 2]. However, the balance of the intestinal microbiota is negatively
influenced by modern lifestyle, leading to increased numbers of pathogenic microorganisms
that disrupt microbial balance and cause a reverse from beneficial to harmful functioning. In
such cases, the external support with probiotics is very welcome and supported by several
scientific studies [3].
According to the Food and Agriculture Organisation of the United Nations (FAO) and the
World Health Organisation (WHO), probiotics are defined as live microorganisms, which
when administered in adequate amounts confer a health benefit on the host [4, 5]. The most
common probiotic bacteria are certain strains from the genera Lactobacillus (i.e., L. rhamnosus,
L. acidophilus, L. plantarum, L. casei, L. delbrueckii subsp. Bulgaricus, etc.) and Bifidobacterium (i.e.,
B. infantis, B. animalis subsp. lactis, B. longum, etc.). Other probiotic bacteria include Pediococcus
acidilactici, Lactococcus lactis subsp. lactis, Leuconostoc mesenteroides, Bacillus subtilis, Enterococcus
faecium, Streptococcus thermophilus, Escherichia coli Nissle 1917, etc. Certain yeasts such as
Saccharomyces boulardii are also probiotics [6, 7].
Probiotics together with other beneficial microbes are commensals of the gut and differ from
pathogenic bacteria in the terms of their actions on immune cells in the gut as they do not
stimulate the proliferation of mononuclear cells or trigger an inflammatory action [8]. Regard‐
less of whether the probiotics are used for human or animal consumption, there are several
characteristics that a probiotic must achieve. Some of the important characteristics of probiotics
include the following: a probiotic must be generally required as safe (GRAS); a probiotic should
exhibit bile and acid tolerance in order to survive the path from the oral cavity to the small
intestine where it lives, multiplies and excretes beneficial nutrients and molecules; a probiotic
should have the ability to adhere to mucus and/or epithelial cells, and/or other surfaces; a
probiotic should be susceptible to antibiotics; a probiotic should exhibit antimicrobial activity
against pathogens [3, 5, 9, 10]. Although it is accepted that probiotics must be of human origin
[4, 5], many authors have found that some strains that are not normally isolated from human
have shown to be effective [11, 12], which negates this requirement. As noted above, one of
the important attributes of probiotics is their antimicrobial effect against pathogens by
maintaining the homeostasis of the intestinal flora. Assessing the antimicrobial effect of various
probiotics against pathogenic microorganisms is the guiding concept of this chapter. This
chapter reviews the principles and results from various authors of different methods for
determining the antimicrobial or antagonistic effect of probiotics against potential pathogens.
2. Antimicrobial or antagonistic properties of probiotics
In literature both the terms “antimicrobial” and “antagonistic” are found to determine the
ability of one species to inhibit the growth of another species. According to the online Ency‐
clopaedia Britannica, “antagonism” refers to an “association between organisms in which one
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benefits at the expense of the other,.” However, this encyclopaedia does not include the adverb
“antimicrobial.” On the other hand, it contains “antimicrobial agent” that refers to “a large
variety of chemical compounds that are used to destroy microorganisms or to prevent their
development..” The online Merriam Webster dictionary defines “antimicrobial” as “destroy‐
ing or inhibiting the growth of microorganisms and especially pathogenic microorganisms”
and “antagonistic” as “showing dislike or opposition: showing antagonism.”
This antimicrobial/antagonistic ability is especially important for probiotics as one of the
functional beneficial requirements of probiotics is a broad antimicrobial spectrum as well as
antagonism against pathogenic bacteria with strong antimicrobial activity. The antagonistic
activity of one microorganism against another can be caused by competitive exclusion,
immune modulation, stimulation of host defence systems, production of organic acids or
hydrogen peroxide that lower pH, production of antimicrobials such as bacteriocins, antioxi‐
dants, production of signalling molecules that trigger changes in gene expression [13–15].
Antimicrobial substances produced by beneficial microorganisms are known to include lactic
acid, acetic acid, formic acid, phenyllactic acid, benzoic acid as well as other organic acids,
short chain fatty acids, hydrogen peroxide, carbon dioxide, acetaldehyde, acetoin, diacetyl,
bacteriocins and bacteriocins‐like inhibitory substances and others [10, 16, 17]. The most
common bacteriocins include lacticin, lactocin, pediocin, pisciolin, enterocin, reuterin,
plantaricin, enterolysin and nisin [18, 19].
3. Methods
3.1. Methods of literature research
A literature overview of three databases was conducted using the two following keywords:
“probiotic” and “antimicrobial” between the years 1980 and 2016. The search yielded 2882,
1017, and 6200 publications in PubMed, Web of Science, and Science Direct databases,
respectively (Figure 1).
Figure 1. Results of the publications in PubMed, Web of Science and Science Direct databases using keywords: “probi‐
otic” and “antimicrobial” between the years 1980 and 2015.
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All three databases showed great increase in the number of publications in the past 10 years.
The highest results were obtained via Science Direct due to the fact that this database includes
various journals and books from the area of food and dairy sciences, the area of probiotics for
animals as well as the area of human probiotics. PubMed on the other hand contains only
research of probiotics for humans. Also, the programs for keyword searching for each chosen
database seem to differ among each other thus yielding very different numbers of publications
in journals, chapters and conference proceedings. The research on the methods for determining
the antimicrobial effect of strain‐specific probiotics was conducted by adding an additional
keyword aside “probiotic.” This keyword described the various investigated methods for
determining the antimicrobial/antagonistic activity of probiotics (i.e., spot‐on lawn, agar spot,
agar well diffusion, paper disc, co‐culturing, in vivo). Of course, it was not possible to screen
every single article therefore only a selection of the most recent or relevant were used.
3.2. In vitro methods for determining the antimicrobial/antagonistic effect of probiotics
against other microorganisms
3.2.1. Spot‐on lawn antimicrobial assay/agar spot antimicrobial assay
The spot‐on lawn antimicrobial assay has been described by several authors. Several modifi‐
cations of the method have been made. Also various other expressions are used such as agar
spot assay, critical dilution assay and deferred antagonism assay [10, 16, 20–22].
One of the simplest published principles of the spot‐on lawn antimicrobial assay (Figure 2a)
consists of the following steps: different nutrients, selective or differential media, are prepared
and various chosen indicator microorganisms or pathogens at different initial concentrations
are either inoculated in a confluent manner after hardening of agar or are mixed with the agar
in liquid state and poured into the plate. Different dilutions of aliquots of the investigated
probiotic or cell‐free supernatant with bacteriocins are then spotted onto the media already
inoculated with chosen indicator microorganisms [20, 23, 24].
After incubation, the antimicrobial activity is expressed either as inhibition zone or as arbitrary
units (AU/mL). The zone of inhibition is noted either as the diameter or the area of the
inhibition zone. The critical dilution is noted as the last dilution that produces a zone of
inhibition larger than 6 mm. Arbitrary units are defined as the reciprocal of the highest dilution
at which the growth of the indicator microorganism or pathogen is inhibited and are calculated
as (1000/a) x D in AU/mL, where a is the aliquot of cell‐free supernatant added to well in µL
and D is the dilution factor [22, 24].
A modification is the agar spot antimicrobial assay (Figure 2b) and consists of the following
steps: MRS agar or other specified agar is prepared and the probiotic bacteria or test cultures
(few µL) are spotted on. These agars are then incubated to develop spots. Next, the indicator
bacteria (pathogenic species, spoilage species and other probiotic species) are mixed into
specific soft agar (0.7%) and poured over a plate. The plates are then incubated aerobically or
anaerobically and the inhibition zones are read. A clear zone of more than 1 mm around the
spot is considered as positive [25]. A third modification is the spot‐on lawn antimicrobial assay
with wells (Figure 2c), which consists of the following steps: chosen nutrients, selective or
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differential media, are prepared. Wells (6 mL, 7 mm or other dimensions) are bored in each
plate and the bottom of the wells is sealed with agar. Aliquots of active cultures at different
dilutions are pipetted into the wells. The plates are left at room temperature to allow migration
and settling of the test cultures. The samples are then incubated for 3 h at 37°C and the plates
are then overlaid with agar seeded with indicator pathogenic microorganisms (or other
indicator organisms) and incubated at suitable incubation conditions. After incubation, the
antimicrobial activity is expressed either as inhibition zone or as arbitrary units (AU/mL) [16].
Figure 2. Schemes of different versions of spot‐on lawn/agar spot assays: (a) simple spot‐on lawn assay, (b) agar spot
assay and (c) spot‐on lawn assay with wells.
The fourth modification is the cross streak assay [26] where each probiotic strain is streaked
in three parallel lines onto agar using a 1‐mL loop. Once these lines have dried, test pathogenic
strains are streaked perpendicular to these initial strains in the same fashion, giving three
possible zones of inhibition for each combination of strains. It was assumed that when there
is inhibition, it is caused by the tester probiotic strain hindering the growth of the second‐
streaked (indicator) strain.
3.2.2. Agar well diffusion assay/paper disc assay
The agar well diffusion assay (AWDA) (Figure 3a) is used for determining the antagonistic
effects of cell‐free supernatants. The general principle of agar well diffusion assay consists of
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the following steps: different nutrients, selective or differential media, are prepared. The plates
are inoculated with the chosen indicator microorganism. The 6‐mm or 7‐mm wells are bored
in each plate. Aliquots of different dilutions of cell‐free supernatants are pipetted into the wells.
After incubation, the antimicrobial activity is expressed either as inhibition zone or as arbitrary
units (AU/mL) [20, 22]. The paper disc assay (Figure 3b) is a modification where instead of
making wells, discs measuring 6 mm are absorbed with aliquots of cell‐free supernatant and
placed on the agar inoculated with indicator strains. After incubation, the inhibition zone is
evaluated based on the clear zone around the paper disc [23].
Figure 3. Scheme of the agar well diffusion assay and paper disc assay: (a) agar well diffusion assay and (b) paper disc
assay.
3.2.3. Co‐culturing assays for determining the antimicrobial activity
Determining the antimicrobial activity of probiotics against common pathogens is also possible
with the co‐culturing assay. This method includes the following steps: preparation of incuba‐
tion media (i.e., nutrient broth, reconstituted skim milk, sterilized milk, yogurt, whey, etc.).
Aliquots of pathogenic and probiotics microorganisms are inoculated into the incubation
media. The samples are mixed well and incubated. After incubation, the population of
pathogenic bacteria are counted on appropriate agars. Values are usually expressed as log cfu/
mL [14–16, 27, 28].
The microtitre plate assay is a version of the co‐culturing assay that includes the following
steps: cell‐free supernatant of active probiotic or other investigated microorganism is prepared
and divided into several parts that undergo different conditions (i.e., NaOH added to neu‐
tralize pH, left acidic, heated, etc.). Pathogenic microorganisms are cultured and added to
appropriate broth. The microtitre plate is used to prepare mixes of probiotics/cell‐free super‐
natants and pathogenic microorganisms and incubated at suitable incubation conditions.
Before and after incubation, the optical density at 620 nm is measured and the suppressive
activity is calculated as a percentage of inhibition of pathogen growth [15].
Another important type of co‐culturing assay is using cell lines. As several important mecha‐
nisms underlying the beneficial effects of probiotics include the effects of probiotic properties
on specific tissues, particularly on the intestine, the evaluation of probiotic effects on human
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intestinal cell lines in vitro is meaningful as these cells mimic the systemic environment of an
organism and are used as a biological matrix alternative to in vivo tests. In fact, in vitro evidence
is particularly important considering that the EU directives tend to discourage in vivo
experiments on animals [29]. Several different cell lines have been used, such as HT‐29 cell line
from human colon [29], IPEC‐J2 porcine neonatal jejunal cell line [30], Vero African green
monkey kidney epithelial cell line [31], Caco‐2 colon adenocarcinoma cell line [32], HIEC‐6
normal epithelial small intestine cell line [33], BALB/c3T3 murine embryonal fibroblast cell
line [29] and many others. Cells are routinely grown in Dubelco's modified Eagles’ medium
(DMEM), McCoy's 5a medium or other medium and seeded in well plates or microtitre plates
that are incubated at 37°C for 24 h in 1 mL medium in 5% CO2. Probiotic and pathogenic
microorganisms are then added and the cell viability is determined after incubation.
3.3. In vivo methods for determining the antimicrobial/antagonistic effect of probiotics
against other microorganisms
For in vivo testing, randomized double blind, placebo‐controlled human trials should be
undertaken to establish the efficacy of the probiotic product. The consultation recognized that
there is a need for human studies in which adequate numbers of subjects are enrolled to achieve
statistical significance. In order to ascertain that a given probiotic can prevent or treat a specific
pathogen infection, a clinical study must be designed to verify exposure to the said pathogen
(preventive study) or that the infecting microorganism is that specific pathogen (treatment
study). If the goal is to apply probiotics in general to prevent or treat a number of infectious
gastroenteritis or urogenital conditions, the study design must define the clinical presentation,
symptoms and signs of infection, and include appropriate controls [4].
However, many scientists have reverted to in vivo animal studies. The animal models do not
necessarily provide scientifically appropriate and relevant results for human, due to obvious
species‐specific differences in anatomy, biochemistry, physiology, pharmacokinetics and toxic
responses. Especially, in medicine and pharmacy, the “safety testing” on animals led to
thousands of deaths worldwide due to the evidence that animal tests are not only worthless,
but they are also dangerously unpredictable. The use of replacement alternative methods,
especially incorporating human cells and tissues, avoids such confounding variables [32].
The European legislation OJ L136 of 08.06.2000 includes the 3Rs regulation that results in
important reduction of studies on animal models and consists of the following. Reduction: using
alternative methods for obtaining comparable levels of information from the use of fewer
animals in scientific procedure or for obtaining more information from the same number of
animals. Refinement: using alternatives methods that alleviate or minimise potential pain,
suffering and distress, and which enhance animal wellbeing. Replacement: using alternative
methods that permit a given purpose to be achieved without conducting experiments or other
scientific procedures on animals [32].
The in vivo animal model antimicrobial study is described as follows: briefly, all animal models
include at least two groups under controlled settings. One group receives chosen probiotic and
pathogen (treated infected group) and the other receives only the pathogen (untreated infected
group). The observed difference includes the exanimation of faeces as well as the examination
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of different cells after scarifying the animals (spleens, lymph nodes, blood, liver, colon, cecum,
etc.). Animals used in these studies include mice, rats, chicks, rabbits, pigs, Fish and even
worms [30, 34–37]. Work is done under accordance with the guidelines of the European
convention for the protection of vertebrate animals used for experimental and other scientific
purposes (Directive 86/609/EEC).
4. Recent results of in vitro antimicrobial/antagonistic assays for various
probiotic strains
The following section contains results of the antimicrobial/antagonistic assays for various
probiotic strains or strains with probiotic‐like properties against various potential pathogens,
spoilage microorganisms, or other probiotic microorganisms. The results reported using
different assays (spot‐on lawn/agar spot, agar well diffusion/paper disc, co‐culturing, micro‐
titre plate and cell line assays) are published by various authors stated in the text and some of
the individual procedures are briefly explained.
4.1. Recent results of selected spot‐on lawn/agar spot antimicrobial assays
The antimicrobial activity of Lactobacillus plantarum EM against seven potential pathogens
using the spot‐on‐lawn assay was conducted by Choi and Chang [10]. The following nutrient
and selective media were used: Luria‐Bertani agar for E. coli O157:H7 ATCC 43895, P. aerugi‐
nosa ATCC 27853, S. enterica serovar Typhi ATCC 19430, nutrient agar supplemented with 2%
NaCl for V. parahaemolyticus ATCC 17802 and tryptic soy agar for B. cereus KCTC 3624, M.
luteus ATCC 15307 and S. aureus ATCC 29123. All potential pathogenic bacteria had an initial
inoculum of 6 log cfu/mL. An aliquot of 10 µL of L. plantarum EM was spotted onto each plate.
The plates were incubated aerobically at 37°C. After incubation the arbitrary units (AU/mL)
were determined. L. plantarum EM exhibited strong antimicrobial activity against the seven
chosen potential pathogenic bacteria. The strongest activity was noted against V. parahaemo‐
lyticus, ATCC 17802 (25600 units) and the weakest activity was noted for S. aureus, ATCC 29123
(200 units). As one of the most important requirements of probiotics is a broad antimicrobial
spectrum, the authors found that L. plantarum EM fulfilled the beneficial requirements of
probiotics [10].
In another research [24], screening for bacteriocins using the spot‐on lawn method was used.
One hundred and fifty lactic acid bacteria were isolated from samples of traditional fermented
Vietnamese pork. The isolate named L. plantarum KL‐1 was found to produce bacteriocins,
effective against various Gram‐positive and Gram‐negative bacteria. The test was conducted
by preparing two layers of soft agar (0.8% agar). The first layers were poured into the plate;
then the top layer, which included 5 mL of soft agar together with 10 µL (about 107 cfu/mL) of
freshly grown test bacterial strains, was added. The Gram‐positive strains included S. aureus
TISTR 118, E. faecalis JCM 5803, E. faecalis TISTR 888, L. lactis subsp. cremoris TISTR1344, L.
mesenteroides JCM 6124, L. mesenteroides TISTR 942, L. sakei subsp. sakei JCM 1157, L. sakei TISTR
890, L. plantarum ATCC 14917, L. inoccua ATCC 33090, Streptococcus sp. TISTR 1030, B. coagu‐
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lans JCM 2257, B. coagulans TISTR 1447 and B. campeatris NBRC 11547. The Gram‐negative test
strains included P. fluorescens TISTR 358, P. fluorescens JCM 5963 and A. hydrophila TISTR 1321.
Bacteriocin activity was tested by spotting 10 µL of previously prepared cell‐free supernatant
(in different dilutions) of the isolate L. plantarum KL‐1. The inhibition zone was observed after
overnight incubation at the proper temperature for each indicator microorganisms and the
spectrum was expressed at arbitrary units (AU) [22]. The results show that the antimicrobial
activity of the bacteriocin was strain specific. The bacteriocin was most effective against both
strains of L. sakei. The bacteriocin was less effective against certain Gram‐positive bacteria (both
strains of E. faecalis, L. plantarum and both strains of L. mesenteroides subsp. mesenteroides).
However, it was not effective against S. aureus, both strains of B. coagulans and any of the chosen
Gram‐negative bacteria.
Tharmaraj and Shah [16] used the spot‐on‐lawn technique with wells to test the inhibition of
chosen pathogenic bacteria (E. coli, S. typhimurium, S. aureus and B. cereus) and spoilage bacteria
(B. stearothermophilus and P. aeruginosa) by one strain of L. casei (Shirota YLC); two strains of
L. paracasei subsp. paracasei (LCS1, LC01), L. acidophilus (LA5, LAC1) and B. animalis (BB12,
BLC1); three strains of P. freudenreichii subsp. shermanii (P, PS1, PB10360) and four strains of
L. rhamnosus (LC705, LBA, LGG, LR1524). MRS agar was used for lactobacilli (L. acidophilus,
L. casei, L. paracasei subsp. paracasei and L. rhamnosus), MRS agar + L‐cysteine (0.05%) for B.
animalis, NaLa agar for P. freudenreichii subsp. shermanii and nutrient agar was used for
pathogenic bacteria. Suitable agar (25 mL) was poured into the plates and wells were cut with
a sterile metal borer. The bottom of the wells was sealed with 0.8% agar. Active culture (50 µL)
of producing probiotics was then filled into the wells and left at room temperature for 2 h,
followed by incubating at 37°C for 3 h. The remaining depth of the well was sealed with 1%
agar. Finally, the spotted plates were overlaid with 10 mL of 0.8% agar seeded with about
107 cfu/mL of pathogenic bacteria. The plates were incubated anaerobically for 72 h at 37°C for
all chosen pathogenic and spoilage bacteria. Both chosen spoilage bacteria were additionally
incubated aerobically for 24 h at 37°C. On average, among all the probiotic and spoilage
bacterial interactions, the spore formers were inhibited by the probiotic microorganisms to a
greater extent (average zone of inhibition, 19 mm) than the non‐spore formers (average zone
of inhibition, 14 mm). Also, the Gram‐positive bacteria (average zone of inhibition, 18 mm)
were inhibited more than the Gram‐negative bacteria (average zone of inhibition, 14 mm).
Strains of P. freudenreichii subsp. shermanii did not show notable inhibitory effect.
Soomro et al. [23] also used the spot‐on lawn method to determine antimicrobial activity of
various Lactobacillus species. They found that L. acidophilus J1 showed an inhibitory effect
against E. coli. The plates were prepared by inoculating 100 µL of indicator strain E. coli grown
in broth with 3.5 mL soft MRS agar and were overlaid over MRS agar. The plates were
incubated for 2 h at 37°C after which 30 µL of cell‐free supernatant of L. acidophilus J1 was
spotted onto the overlaid surface. The pH of the cell‐free supernatant was adjusted to 5.5 to
eliminate the effect of organic acids and hydrogen peroxide. The plates were incubated at
37°C for 18 h and were subsequently examined for inhibition zones. It was found that the
inhibitory effect against E. coli was due to the production of a bacteriocin.
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Probiotic strains or strains with probiotic
potential with efficient antimicrobial
activity in vitro
Indicator pathogenic microorganisms Reference
Lb:L. casei C1; L. plantarum C4 G+:L. monocytogenes
G‐:S. Typhimurium CECT 4157, Y. enterocolitica IP383
[35]
Lb:Lactobacillus MSMC64‐1 G+: MRSA DMST 20651, 20654, G‐: S. Typhi DMST 5784, V.
parahaemolyticus DMST 5665, S. dysenteriae DMST 15111
[38]
Oth:S.cerevisiae JCM7255 G+:S. agalactiae [39]
Oth:B. pumilus B16, B. mojavensis J7 G‐:V. parahaemolyticus [40]
Lb:L. acidophilus La‐5, Bb: B. longum ATCC
15707
G+:S. aureus, L. monocytogenes;G‐:E. coli O157:H7 [41]
Lb:L. acidophilus JN188382, L. fermentum
JN188383, L. fermentum JN188384, L. buchneri
JN188385, L. buchneri JN188386, L. buchneri
JN188387, L. casei JN188388, L. casei JN188389,
L. casei JN188390
G+:E. faecium ATCC 51558, S. epidermidis ATCC 12228, P. acnes
ATCC 6919, L. monocytogenes, S. aureus S244; G‐: E. coli ATCC
29181, K. pneumoniae K36, E. cloacae, S. sonnei ATCC 25931, H.
pylori ATCC 43579, V. parahaemolyticus, fng: C. albicans ATCC
44831
[42]
Oth:E. faecium CV1, LPP29, W. cibaria P71, L.
lactis subsp. cremoris SMF110, Lc.
mesenteroides subsp. cremoris SMM69, P.
pentosaceus SMM73, TPP3
G‐:T. maritimum NCIMB2154, LL01.8.3.8, V. splendidus
CECT528, DMC‐1
[43]
Lb:L. plantarum P6 G+:S. aureus ATCC 25923, B. cereus, L. ivanovii ATCC
19119;G‐:E. coli ATCC 25921, S. enterica, P. aeruginosa
[44]
Oth:E. faecalis AP‐216, E. faecalis AP 45 G+:C. perfringens KCTC 3269, KCTC 5100, L. monocytogenes
KCTC 3569, 3586, 3710
[45]
Oth:B. subtilis DCU, B. pumilus BP, B. cereus
HL7
G‐:V. parahaemolyticus [46]
Lb: LAB 18, LAB 48 G‐:S. enterica serovar Enteritidis phage type 13A, E. coli
O157:H7, C. jejuni
[47]
Lb:L. plantarum CK06, CK19, B01, B07, K09,
K10, K21, LM11, ZS07, ZS11 and ZS15
G+:S. aureus SSV25, S. epidermidis SSV30, S. lentus CCM
3472, E. faecalis V583, L. monocytogenes CCM 4699, G‐: A.
calcoaceticus CCM 4503; S. paucimobilis CCM 3293; S. enterica
subsp. enterica TA100 CCM 3812
[48]
Lb:L. fermentum PXN 44, L. plantarum PXN 47 G+:E. faecalis NCTC 00775; G‐: E. coli NCTC 9001 [49]
Lb:L. paraplantarum FT259 G+:L. monocytogenes IAL 633, L. innocua ATCC 3309 [50]
Where probiotics are divided as follows: lb: lactobacilli; bb: Bifidobacterium; oth: other; and pathogens are divided as
follows: G+: Gram positive; G−: Gram negative; fng: fungi.
Table 1. A selection of assays published since 2013 of successful antimicrobial activity of chosen probiotics using the
spot‐on lawn/agar spot assay on chosen pathogenic microorganisms.
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Assays published since 2013 of antimicrobial activity of chosen probiotics using the spot‐on
lawn/agar spot assay on chosen pathogenic microorganisms are noted in Table 1.
As noted in Table 1, the most common investigated probiotic strains or strains with probiot‐
ic potential were from the genus Lactobacillus (L. plantarum, L. acidophilus, L casei and L.
fermentum). Several studies included probiotic strains of the genus Bacillus. The most com‐
mon pathogens included in the assays were S. aureus, L. monocytogenes, E. coli, Vibrio spp. and
Salmonella spp. One study examined the antimycotic properties of probiotics against various
strains of the genus Aspergillus. Different strains of E. faecium were on the one hand used as
probiotics and on the other hand used as potential pathogen, thus proving the dualistic nature
of this species.
4.2. Recent results of selected agar well diffusion assays/paper disc methods
The agar well diffusion assay was conducted in the research by Ali et al. [51], where 14 isolates
with probiotic potential were screened for antimicrobial activity against E. coli and S. aureus.
The probiotic isolates were identified as two Lactobacillus spp. (S2a3 and S4b1), eleven
Bifidobacterium spp. (FCb1, Kb2, LZa7, LZb8, RC1b8, RC2b4, RC4a3, RC4b2, SCa4, SCb2 and
Y2a5) and one Streptococcus spp. (RC2b3). A volume of 100 µL of cell‐free supernatant of
isolates with probiotic potential was filled in 7‐mm wells cut in nutrient agar previously
inoculated with E. coli or S. aureus. The diameter of inhibition zone was measured after 48 h
of incubation. The supernatant obtained from all 14 isolates exhibited varying degrees of
inhibitory activity against S. aureus and E. coli. The isolates LZb8, S4b1 and RC4a3 exhibited
the superior antibacterial activity with inhibition zones ranged 8.3–8.4 mm. The least activity
was recorded for the isolates SCa4 and RC4b2 (inhibition zone ranged 2.3–2.5 mm), whereas
the isolates Kb2, LZa7, RC2b4, RC2b3, SCb2 and Y2a5 (inhibition zone ranged 3.5–4.8 mm)
were moderately active against S. aureus. It is worth mentioning that the inhibitory activity of
the tested isolates supernatants was slightly less against E. coli as compared to that obtained
against S. aureus, indicating that E. coli could be less sensitive.
In the previously mentioned research by Soomro et al. [23], the paper disc method was also
used. Sterile filter discs measuring 6‐mm diameter with an absorbed aliquot of 20 µL of cell‐
free supernatant of L. acidophilus J1 were placed on MRS and nutrient agar plates containing
the target strain E. coli. After incubation at 37°C, the inhibitory activity was evaluated. It was
found that the paper disc assay yielded an inhibition zone of 10 mm and was more appropri‐
ate compared to the spot‐on lawn assay.
Assays published since 2013 of antimicrobial activity of chosen probiotics using the agar
well diffusion assay or the paper disc assay on chosen pathogenic microorganisms are noted
in Table 2. The results show that the agar well diffusion assay or the paper disc assay is the
most common method used for determining the antimicrobial or antagonistic effect. The
most common investigated probiotic strains or strains with probiotic potential were again
from the genus Lactobacillus. Some assays included bifidobacteria and bacteria from the ge‐
nus Pediococcus and Lactococcus. The most common pathogens included in the assays were
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again S. aureus, L. monocytogenes, E coli, Vibrio spp., Aeromonas spp. Salmonella spp. and Pseu‐
domonas aeruginosa. One study even assessed the antagonistic activity of probiotics against
herpes simplex virus types 1 and 2 and one study investigated the antimicrobial activity of
probiotics against the protozoa Giardia lamblia. However, using cell‐free supernatants does
not mimic real conditions. Therefore, further assays are necessary.
Probiotic strains or strains with probiotic
potential with efficient antimicrobial
activity in vitro
Indicator pathogenic microorganisms Reference
Lb:L. acidophilus PBS066, L. fermentum
PBS073,
L. plantarum PBS067, L. rhamnosus PBS070, L.
reuteri PBS072, Bb: B. animalis subsp. lactis
PBS075, B. longum subsp. longum PBS108
G+:S. aureus ATCC 6538, E. faecalis ATCC 29212, G‐: E. coli
ATCC 25922, P. aeruginosa ATCC 9027, fng: C. albicans ATCC
10231
[29]
Lb:L. salivarius JM41, JK21V, JM31, JS2A,
JM14, JK22, JM2A1 and JM32, L. plantarum
PZ01 Oth: P. acidilactici JM241 and JH231, P.
pentosaceus JS233, E. faecium JS11
G+:S. aureus ATCC 29213, G‐: E. coli K88, 25922 and 1569, S.
Enteritidis ATCC 13076, S. Typhimurium ATCC 14082
[34]
Lb:L. casei
C1, L. plantarum C4, L. acidophilus
G+:L. monocytogenes,G‐:E. coli C17, S. enterica ser Typhimurium
CECT4156, Y. enterocolitica IP383
[35]
Lb:Lactobacillus MSMC64‐1 G+: MRSA DMST 20651, 20654, G‐: S. Typhi DMST 5784, V.
parahaemolyticus DMST 5665, S. dysenteriae DMST 15111
[38]
Lb:L. acidophilus La‐5, Bb: B. longum
ATCC15707
G+:S. aureus, L. monocytogenes,G‐:E. coli O157:H7 [41]
Lb:L. plantarum WCFS1, L. plantarum NA7 G+:L. monocytogenes CIP 81.3 ILSI NA 39, G‐: E. coli O157:H7
ATCC 43888, S. enterica ser Enteritidis CIP 81.3
[52]
Lb:L. casei PTCC 1608, L. rhamnosus PTCC
1637
G‐:P. aeruginosa PTCC 1430 [53]
Oth:B. amyloliqufaciens G+:C. difficile [54]
Oth:P. pentosaceus KID7 G+:S. aureus KCCM1133515, MRSA CCM40510, S. epidermidis
KCTC 191712, L. monocytogenes KACC1076420, B. cereus
KACC11240 G‐: S. Typhi KCTC2514, S. choleraesuis
KCTC293215, S. gallinarum KCTC293126, S. boydii KACC10792
14, Y. enterocolitica KACC1532020, E. coli O138KCTC261511,
O1KCTC2441, P. aeruginosa KCCM 1180218,
[55]
Lb:L. rhamnosus FM13, FM14, FM22, FS2,
FS10, PS2, PS11, SF6, SP13, L. paracasei CM1,
CM2, MF5, PM8
G+:S. aureus ATCC 6538, L. monocytogenes DSM 12464, E.
faecalis, G‐: E. coli ATCC 25922
[56]
Lb: L. casei LC‐01, L. acidophilus LA‐5, L.
paracasei
fng:A. niger PTCC 5012, A. flavus PTCC 5004, A. parasiticus
PTCC 5286, P. chrysogenum PTCC 5035
[57]
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Probiotic strains or strains with probiotic
potential with efficient antimicrobial
activity in vitro
Indicator pathogenic microorganisms Reference
Lb:L. viridescens NRRL B‐1951 G+:L. monocytogenes CWD 1002, CWD 1198 [58]
Lb:L. plantarum S2 G+:S. aureus CMCC2607, G‐: E. coli CMCC44825,
S. Typhimurium CMCC50115, S. flexneri CMCC51061
[59]
Oth:B. subtilis JQ302302, B. aerophilus
JQ312663
G‐:A. hydrophila ATCC 49140, MTCC 1739, Aeromonas sp.
JX136697, JX136698, A. enteropelogenes JX136699, P. rettgeri JX
136696
[60]
Lb:L. acidophilus L‐1, L. bulgaricus 6, L.
plantarum 24‐4B, L. fermentum 1, L. brevis, Bb:
B. animalis subsp. lactis L‐3
G+:S. aureus, B. cereus
G‐:E. coli
[61]
Lb:L. plantarum DK211, DK303; L. paracasei
DK215, L. sakei DK301
G+:S. aureus KCTC 3881, E. faecalis KCTC 2011, B. cereus KCTC
3624
[62]
Lb: L. mesenteroides subsp. mesenteroides SD1,
SD23, SF2, SF3
G+:S. aureus ATCC 25923, FRI 184, L. monocytogenes ATCC
19115, G‐: E. coli ATCC43895, S. enterica ATCC 14028
[63]
Oth:L. mesenteroides MTCC 5442, B. subtilis G‐:V. cholerae [64]
Lb:L. fermentum M059, L. fermentum F‐6,
Oth: W. cibaria 4213
G+:S. aureus ATCC 6538, B. cereus NCIM 245, B.
subtilis ATCC 6633, G‐: E. coli ATCC 25922, S. Typhi 25,
P. aeruginosa ATCC 27853
[65]
Lb:L. brevis DT24 G‐:E. coli MTCC 729 [66]
Lb:L. rhamnosus (4 strains) G‐:Helicobacter pylori [67]
Lb:L. plantarum, L. salivarius G+:S. aureus ATCC 6538S, C. perfringens ATCC 13124, G‐: E. coli
ATCC 8734, S. Enteritidis ATCC 13311, R. anatipestifer ATCC
11845, P. multocida ATCC 43137
[68]
Lb:L. acidophilus P106, L. plantarum P164 Prs:Giardia lamblia [69]
Lb:L. casei G‐: S. flexneri, S. sonnei [70]
Lb:L. helveticus PJ4, L. plantarum PJ7 G+:S. aureus MTCC737, G‐: E. coli MTCC443, S.
Typhimurium MTCC733, S. fleksneri MTCC1457,
P. aeruginosa MTCC1688
[71]
Lb:L. salivarius K35, K43 G+:S. mutans ATCC 25175 [72]
Oth:B. amyloliquefaciens KATMIRA1933 Vr: Herpes simplex virus types 1 and 2 [73]
Oth:B. amyloliquefaciens FPTB16 G‐:E. tarda, A. hydrophila, V. harveyi, V. parahaemolyticus [74]
Where probiotics are divided as follows: lb: lactobacilli; bb: Bifidobacterium; oth: other; and pathogens are divided as
follows: G+: Gram positive; G−: Gram negative; fng: fungi; prs: parasite.
Table 2. A selection of assays published since 2013 of successful antimicrobial activity of chosen probiotics using the
agar well diffusion assay or the paper disc assay on chosen pathogenic microorganisms.
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4.3. Recent results of selected co‐culturing assays
The influence of the potential pathogenic bacteria P. aeruginosa ATCC 27853 against various
combinations of probiotic supplements and the kefir microbiota was investigated using the
co‐culturing method [6]. One multispecies, one oligospecies and one monospecies probiotic
supplement as well as kefir microbiota from kefir grains originally from the Caucasian
mountains were used. The multispecies supplement contained L. acidophilus (NIZO 3678;
NIZO 3887), L. paracasei NIZO 3672, L. plantarum NIZO 3684, L. rhamnosus NIZO 3689, L.
salivarius NIZO 3675, B. bifidum NIZO 3804, B. lactis NIZO 3680 and E. faecium NIZO 3886. The
oligospecies supplement contained L. acidophilus LA‐5, B. infantis BB‐12 and E. faecium. The
monospecies supplement contained L. reuteri DSM 17938. Co‐culturing was conducted by
adding 1 mL of probiotic samples and 1 mL of overnight P. aeruginosa suspension in 40 mL
previously sterilized bovine milk. Samples were incubated for 4 days at 25°C with agitation
(250/min). After incubation, serial 10‐fold dilutions were prepared for all samples and the P.
aeruginosa populations were enumerated on cetrimide agar with added glycerol. It was found
that the P. aeruginosa population in milk without probiotics reached an average of 9.2 log/mL,
whilst the P. aeruginosa population in milk reached 5.2, 8.3, 8.3 and 5.0 for the samples with
the multispecies, oligospecies and monospecies probiotic supplement as well as the kefir
microbiota respectively. This research thus found that the decrease of the potential pathogen
P. aeruginosa was dependent on the type of probiotic microbiota and that both multispecies
microbiota (multispecies probiotic supplement kefir microbiota) with a much more diverse
population than the other two samples (oligospecies probiotic supplement and the monospe‐
cies supplement) exhibited an efficient synergistic effect [7]. Both samples also exhibited a
higher increase in the total population of anaerobic microorganisms after fermentation with
P. aeruginosa thus indicating that a more successful quorum‐sensing regulatory network was
established and yielded antagonistic effects against the potential pathogen P. aeruginosa.
Tharmaraj and Shah [16], as already mentioned in the previous section, also investigated the
inhibition effect of various probiotics against chosen pathogenic and spoilage bacteria with
the co‐culturing method. Briefly, 9 mL of reconstituted skim milk was inoculated with 1 mL
of overnight culture of probiotic bacteria and 0.1 mL of pathogenic or spoilage bacteria. The
medium was mixed well and incubated at 37°C for 24 h. / were counted on nutrient agar and
the log population calculated (Table 6). All four pathogenic bacteria were inhibited by all
probiotic strains tested to varying degrees. On average, the probiotic bacteria reduced the
population of pathogenic bacteria by 2.8 log units. B. cereus was inhibited to a greater degree
by all probiotic bacteria and strains than other pathogenic bacteria. On average, the inhibito‐
ry effect of all probiotic bacteria and strains was the weakest against E. coli. S. aureus was
inhibited to a greater degree by B. animalis and L. rhamnosus than the other probiotic bacteria.
Ratsep et al. [15] published their research of a microtitre plate assay on the antimicrobial effect
of L. plantarum (five strains: N11, N27, N33, N44 and E) supernatant against various C. difficile
strains (six clinical isolates from Norwegian patients, six clinical isolates from Estonian patients
and two reference strains: VPI 10463 and M13042). Overnight C. difficile cultures were added
to BHI broth with a density according to McFarland 3.0. Various reaction mixes were pre‐
pared (natural (acidic), neutral (pH 6.0) and neutral, heated for 20 min at 100°C) and incubat‐
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ed under anaerobic conditions for 48 h at 37°C. The optical density at 620 mm was measured
at the beginning of incubation and after 48 h and the suppressive activity of L. plantarum strains
calculated as a percentage of inhibition. The highest inhibitions of C. difficile growth were in
the samples of heated neutralized supernatants and the lowest in cases of the neutralized
samples. There was statistically higher inhibition in heated neutralized supernatants versus
neutralized supernatants of N11 and E56 lactobacilli strains. When comparing antagonistic
activity of L. plantarum strains, there was a relevant difference only between N11 and N33
strains in the samples of heated neutralized supernatants. The neutralization of supernatant
did not reduce its inhibitory effect. Thus, lowering the pH of the environment is not the main
mechanism in inhibition of C. difficile by lactobacilli. Also heating of supernatant did not reduce
its activity; thus, some thermostable compounds may be involved in the inhibition. The above‐
mentioned authors [15] also performed the co‐culturing assay with the L. plantarum strains and
C. difficile strains by inoculating 50 mL of brain heart infusion broth with 50 µL of lactobacilli
suspension and 50 µL of C. difficile suspension and incubating under anaerobic conditions
for 48 h at 37°C. After incubation, serial 10‐fold dilutions were prepared and the C. difficile
populations were enumerated on fastidious anaerobe agar. It was found that the five L.
plantarum strains (N11, N27, N33, N44 and E) were able to inhibit the growth of the 14 C. difficile
strains (six clinical isolates from Norwegian patients and Estonian patients and two refer‐
ence strains: VPI 10463, M13042) in the co‐culture incubation as the average log cfu/mL after
48 h was 3.0, whereas the average log cfu/mL of the C. difficile strains alone was 7.0.
Another important co‐culturing method is the use of cell lines as noted in the research by Abdel
et al. [31] of 12 lactobacilli isolates interfering with the adherence and invasion of S. Typhi 66
using kidney epithelial cell line Vero (ATCC CCl‐81). The same authors also investigated this
interference with the co‐culturing assay in MRS broth. It was found that nine lactobacilli
isolates inhibited the growth of S. Typhi in the co‐culturing assay. Nine lactobacilli isolates
were also successful in achieving a >50% inhibition of adherence of S. Typhi isolate (SS6) to
Vero cells.
Assays published since 2013 of antimicrobial activity of chosen probiotics using various co‐
culturing assays on chosen pathogenic microorganisms are noted in Table 3. The results were
similar to the results of spot‐on lawn and agar well diffuse assays.
Probiotic strains or strains with probiotic potential
with efficient antimicrobial activity in vitro
Indicator pathogenic microorganisms Reference
Lb:L. plantarum FH185 G+:S. aureus,G‐:S. Typhimurium [9]
Lb:L. acidophilus La‐5, Bb: B. longum ATCC15707 G+:S. aureus, L. monocytogenes,G‐:E. coli O157:H7 [41]
Lb:L. acidophilus P106, L. plantarum P164 Prs:Giardia lamblia [69]
Lb:L. rhamnosus GR‐1, L. reuteri RC‐14 Fng:C. glabrata [75]
Lb:L. helveticus KLDS 1.8701 G+:S. aureus ATCC 25923, L. monocytogenes ATCC
19115, G‐: E. coli O157:H7 ATCC 43889, S.
Typhimurium ATCC 14028
[76]
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Probiotic strains or strains with probiotic potential
with efficient antimicrobial activity in vitro
Indicator pathogenic microorganisms Reference
Lb:L. reuteriOth:B. subtilis MA139 G‐:E. coli K88 [77]
Lb:L. plantarum C014 G‐:A. hydrophila TISTR 1321 [78]
Lb:L. acidophilus, Oth:Pediococcus G‐:S. Enteritidis 13A [79]
Lb:L. paracasei CNCM I‐4034, L. rhamnosus CNCM
I‐4036, Bb: B. breve CNCM I‐4035
G‐:E. coli ETEC CECT 501, S. Typhimurium CECT
443 S. Typhi CECT 725, S. sonnei CECT 457
[80]
Lb:L. fermentum 907, Bb: B. longum 1011 G‐:E. coli O157:H7, E. coli O86 [81]
Where probiotics are divided as follows: lb: lactobacilli; bb: Bifidobacterium; and pathogens are divided as follows: G+:
Gram positive; G−: Gram negative; fng: fungi; prs: parasite.
Table 3. A selection of assays published since 2013 of successful antimicrobial activity of chosen probiotics using the
co‐culturing assay on chosen pathogenic microorganisms.
5. Recent results of in vivo antimicrobial/antagonistic assays for various
probiotic strains
5.1. Recent results of determining the in vivo antimicrobial assays using animal models
In the research by Mazaya et al. [36], both in vitro and in vivo studies were conducted. The
significant in vitro antimicrobial activity (no method specified) of two lactobacillus strains
isolated from Egyptian dairy products (L. plantarum LA5 and L. paracasei LA7) was found
against several potential pathogens: S. aureus ATCC 25923, B. subtilis ATCC 23857, M. luteus
ATCC 21882, P. aeruginosa ATCC 27853 and S. Typhi. In vivo assays were also conducted on
5‐week‐old male mice, divided into six groups (10 mice/group). Animals within different
treatment groups were treated daily for 8 days as follows: Group 1, untreated control; Group 2,
animals challenged with single inoculation S. Typhi (200 µL aliquot of 1X 108/P.O); Group 3,
animals treated orally with L. plantarum (LA5) (200 µL aliquot of 1X 108/P.O) for 7 days;
Group 4, animals treated orally with L. paracasei (LA7) (200 µL aliquot of 1X 108/P.O) for 7
days; Group 5, animals challenged with single inoculation S. Typhi, then treated with LA5 for
next 7 days; Group 6, animals challenged with single inoculation S. Typhi and treated with
LA 7 for next 7 days. Administration of LA5 or LA7 counteracted the pathogenic effect
resulting from Salmonella infection. The lactobacilli succeeded to get rid of salmonellosis based
on its phagocytic and immunostimulant activity against typhoid antigen.
Lazarenko et al. [82] conducted an in vitro and in vivo assay to determine anti‐staphylococcal
actions of certain probiotic cultures (L. casei IMV B‐7280, L. acidophilus IMV B‐7279; B. longum
VK1 and B. bifidum VK2). In vitro assay using perpendicular strokes yielded antagonistic
activity against all three strains of S. aureus (209‐P, 43, 8325‐4). The in vivo study with S. aureus
8325‐4 on mice showed that the combination of probiotics (L. casei IMV B‐7280, B. longum VK1
and B. bifidum VK2) was most successful as after day 9 no colonies of S. aureus 8325‐4 were
found in the vagina of the mice.
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In the study by Bujalance et al. [35], a lack of correlation between in vitro and in vivo meth‐
ods of the antimicrobial activity of probiotic lactobacilli against enteropathogenic bacteria was
determined. In this study, the in vitro assay using the agar spot test showed that 20 strains of
probiotic lactobacilli successfully inhibited Y. enterocolitica, S. enterica ser Typhimurium and L.
monocytogenes. However, in the in vivo study using mouse models the selected strains (L. casei
C1 and L. plantarum C4) lacked protective effects against S. Typhimurium. Similar conclu‐
sions of finding no antagonism in vivo are noted in the study by Bratz et al. [83]. Another
study [79] found that the tea Yerba mate exhibited antagonistic activity in vitro but as a feed
additive did not reduce S. Enteritidis colonization in vivo in broiler chickens. These studies
prove that successful in vitro assays do not necessarily mean that the chosen microorganism
with probiotic properties will be successful in real conditions. On the other hand, in vivo animal
studies do not automatically prove antagonism in humans or other species. Therefore, the
justification of using vertebrate animal models is questionable [32]. Gupta et al. [84] used
Drosophila melanogaster commonly known as the “fruit fly,” instead of a vertebrate animal
model. It is a eukaryotic organism and is considered an alternative in the drug discovery
process, mainly because the key physiological processes are well conserved from fly to
humans. Moreover, a short life cycle, distinct developmental stages, easy cultivation, numer‐
ous offspring and a strong cytogenetic/genetic background make Drosophila a model organ‐
ism to study many biological processes including toxicity testing. Zhou et al. [30] used porcine
neonatal jejunal epithelial cell lines (IPEC‐J2) for in vitro assay and worms (Caenorhabditis
elegans) for in vivo testing of lactobacilli isolates against enterotoxigenic E. coli
Probiotic strains or strains with probiotic
potential with efficient antimicrobial activity
in vivo using animal models
Indicator pathogenic microorganisms Reference
Lb:L. reuteri CL9, K16, K67 and S33 G‐:E. coli O149: K88 JG280 [30]
Lb:L. salivarius JM32, L. plantarum PZ01 Oth:
P. acidilactici JH231
G‐:S. Enteritidis ATCC 13076 [34]
Lb:L. plantarum LA5 and L. paracasei LA7 G‐:S. Typhi [36]
Oth:B. amyloliqufaciens G+:C. difficile [54]
Lb:L. plantarum C014 G‐:A. hydrophila TISTR 1321 [78]
Lb:L. casei B–7280, Bb: B. longum VK1, B. bifidumVK2 G+: S. aureus8325–4 [82]
Lb:L. plantarum LR/14 Ins:Drosophila melanogaster [84]
Lb:L. acidophilus CH1 Prs:Enterocytozoon bieneusi [85]
Oth:Pseudoalteromonas sp. G‐:V. harveryi ATCC 14126 [86]
Where probiotics are divided as follows: lb: lactobacilli; bb: Bifidobacterium; oth: other; and pathogens are divided as
follows: G+: Gram positive; G−: Gram negative; fng: fungi; prs: parasite; ins: insect.
Table 4. A selection of assays published since 2013 of successful antimicrobial activity of chosen probiotics using the in
vivo animal models on chosen pathogenic microorganisms.
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The most recent in vivo antagonistic assays using animal models are noted in Table 4. These
results confirm the strain specific antagonistic activity of chosen probiotics.
5.2. Recent results of determining the in vivo antimicrobial assays using clinical trials
Most important research on the antagonistic effect of probiotics are clinical trials, however only
a few well conducted clinical studies have been reported. Most clinical studies include the
comparison of antibiotic therapy with adjuvant probiotic therapy. In the study by Dore et al.
[87], in this prospective, single centre, open label pilot study, patients scheduled for upper
endoscopy for any reason and found to be positive for H. pylori infection were invited to enter.
The intervention consisted of L. reuteri (DSM 17938, Reuflor, BioGaia AB, Sweden) 108 cfu/
tablet plus pantoprazole (proton pump inhibitor) 20 mg twice a day. A 76% decrease in urease
activity was observed. The absence of a control group with pantoprazole without L. reuteri
however prevents any definite conclusion.
In the study by Pendharkar et al. [88] the clinical outcome for women conventionally treated
for bacterial vaginosis and yeast infection with probiotics bacilli was investigated. This study
is an example of the antibiotic therapy with adjuvant probiotic therapy. In the clinical trial,
women were recruited in three groups as follows: women with bacterial vaginosis receiving
clindamycin and metronidazole treatment together with a prolonged administration of
EcoVag® (containing L. rhamnosus DSM 14870 and L. gasseri DSM 14869) for 10 consecutive
days after each antibiotic treatment followed by weekly administration of capsules for next
four months, women with recurrent vulvovaginal candidiasis receiving extended flucona‐
zole and EcoVag® treatment, and women receiving extended fluconazole treatments only.
The 6‐ and 12‐month cure rates for bacterial vaginosis were 67 %. The 6‐ and 12‐month cure
rates for vulvovaginal candidiasis were 100 and 89% in women receiving fluconazole and
EcoVag®, and 100 and 70% in women receiving fluconazole only. The study suggests that the
treatment with antibiotics or anti‐fungal medication in combination with EcoVag® capsules
provide long‐term cure against bacterial vaginosis and R‐VVC.
Some of the most recent in vivo antagonistic clinical trials are noted in Table 5. These results
confirm that adjuvant therapy with antibiotics and chosen probiotics enhances the antagonis‐
tic activity.
Probiotic strains with efficient
antimicrobial activity using in vivo




Basic therapy Type of
trial
Reference
Lb:L. reuteri DSM 17938 G+:H. pylori Proton pump inhibitor:
pantoprazole
CT [87]
Lb:L. rhamnosus DSM 14870, L. gasseri
DSM 14869





Lb:L. rhamnosus GG (LGG), Bb: B.
bacterium BB‐12
G+:H. pylori Standard triple H. pylori
eradication therapy with
DBRCT [89]
Probiotics and Prebiotics in Human Nutrition and Health208
Probiotic strains with efficient
antimicrobial activity using in vivo










Lb:L. rhamnosus GG (LGG), L.
acidophilus La‐5, Bb: B. bacterium BB‐12
Dis: AAD Antibiotics: broad spectrum
oral antibiotics
DBRCT [90]
Lb:L. acidophilus, L. paracaseiBb:B. lactis
At: bismuth




Lb:L. casei DN‐114001 Dis: AAD Antibiotics: broad spectrum
oral antibiotics
CT [92]
Lb:L. acidophilus, l. rhamnosus, L.
acidophilus, L. bulgaricus, Bb:B.
bifidusOth:S. Thermophilus
Dis: bacterial vaginosis Antibiotic: metronidazole CT [93]
Where probiotics are divided as follows: lb: lactobacilli; bb: Bifidobacterium; oth: other; pathogens are divided as follows:
bc: bacteria; G+: Gram positive; G−: Gram negative; fng: fungi; and clinical trials are divided as follows: DBRCT: double‐
blinded randomized clinical trial; CT: clinical trial; AT: additional therapy; Dis: disease; AAD: antibiotic associated
diarrhoea.
Table 5. A selection of published since 2013 of antimicrobial activity of chosen probiotics using in vivo clinical trials on
chosen pathogenic microorganisms or treatment of diseases.
6. Discussion and conclusions
The antimicrobial ability of probiotics is a very important trait and includes the production of
antimicrobial compounds, competitive exclusion of pathogens, enhancement of the intesti‐
nal barrier function and others. Usually, probiotic strains produce more than one antimicro‐
bial substance that may act synergistically, increasing the spectrum of targeted
microorganisms. This property may be desirable as long as this antimicrobial spectrum is
restricted to pathogenic microorganisms but it cannot be excluded that it will not affect the
normal microbiota of the gut or other microbiotas as well [94]. The results show that probiot‐
ic properties are strain dependent and that strain identification is imperative [3].
Probiotic candidates have been accessed from very diverse habitats including faeces of breast‐
fed human infants [65, 69, 80, 85, 95], faeces of healthy adults [9, 15, 65, 70], faeces of elderly
[81], faeces of children [25, 96], breast milk [42], human saliva [52], vaginal isolates of healthy
women [66, 75], various fermented foods or beverages including raw or fermented milk [23,
35, 44], kefir [97], cheese [51, 56, 98], whey [99], yogurt [16, 41], dahi [100, 101], other dairy
products [25, 36, 61], sourdough [102], sausages [17], fermented meat [24], kimchi [10, 62],
maize [25, 59], fermented olives [103], Yerba mate [79], ragi [64], soy sauce [86], soil [104], as
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well as animal origin including rat faeces [71], geese [68], calves [105], pigs [45], fish [39, 60,
63, 78] and other seafood [40, 43, 46] and many others.
By far, the most commonly investigated probiotic were bacteria of the genus Lactobacillus (L.
plantarum, L. acidophilus, L. fermentum, L. casei, L. paracasei and L. reuteri). The genus Bifidobac‐
terium and other probiotic microorganisms (Lactococcus, Pediococcus, Enterococcus, Bacillus and
Saccharomyces) have been also been investigated, but to a somewhat lesser extent. Studies were
also conducted on known probiotics from various tissue type collections. The most common
pathogens used to test the antagonistic activity of probiotics were different strains of S. aureus,
E. faecium, E. faecalis, L. monocytogenes, E. coli, various Salmonella, Vibrio and Yersinia spp.,
and P. aeruginosa.
The antimicrobial activity of probiotic microorganisms has a very wide area application
including adjuvant therapy to antibiotic consumption or for correcting dysbiosis of the
gastrointestinal tract microbiome due to diarrhoea [37, 38, 106], antagonistic activity in humans
against urinary tract infections [26, 66, 75], eradicating H. pylori infections [87], nosocomial
infections [15, 96], dental biofilm formation [72], lowering serum cholesterol [10, 55], treating
fevers [31], as well as in the agro‐food industry for manufacturing fermented products [44, 62,
107], preventing food spoilage [16, 23, 41], as food additives for functional foods [50, 56, 57,
59, 67, 97], as prophylactic agents, adjuvants or alternatives to antibiotic therapies to antibiot‐
ic therapy in poultry [34, 47, 68], cattle [105, 108], pigs [45], fish [74, 78] and other livestock
industry [104], just to name a few.
The process of determining antimicrobial properties of probiotic is complex and includes in
vitro assays, in vivo models or substitute models, clinical studies, metagenomic analyses and
mathematical modelling. Only after all these steps are completed, a probiotic candidate can
be identified as such [109]. In vitro studies are the most represented. Although, they are a crucial
step in selecting probiotic candidates, they are only the first step as efficient antimicrobial
activity via in vitro studies does not necessarily mean that the antimicrobial activity is present
in in vivo assays. Therefore, further research methods (double‐blinded randomized clinical
trials) are necessary to prove the important antimicrobial trait of probiotic candidates. As noted
in Section 5.2, there are only a few well‐conducted published clinical studies. Most clinical
studies include the comparison of antibiotic therapy with adjuvant probiotic therapy which is
an important aim of probiotic consumption.
There is a clear need for more elaborate assays that would better represent the complex
interactions between the probiotics and the host microbiome to understand the consequen‐
ces of the in situ production of antimicrobials by the former [94]. Another important fact is that
probiotics are often found to have higher antagonist activity as multispecies groups [6, 7, 26].
Quorum sensing among probiotics is also an important factor; however, quorum‐sensing
studies among probiotics are sparse. It is well known that microorganisms coordinate
collective behaviour in response to environmental challenges using sophisticated intercellu‐
lar communication networks and that they are not limited to communication within their own
species but are capable of intercepting messages and coerce cohabitants into behavioural
modifications [110], therefore probiotics are included. Although all these facts make re‐
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search of the antimicrobial/antagonistic activity of probiotics even more complex, it also
presents a great opportunity for future research.
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